BMRN · BioMarin Pharmaceutical Inc.
AI read · Good for BMRN
The AI's read
BioMarin agreed to buy Alesta for $275 million to secure ALE1, an oral Phase 1/2a candidate for hypophosphatasia. That matters because HPP currently has one approved therapy that generated roughly $1.7 billion in 2025. The market barely moved, BMRN is up ~1.1% while RSI sits at 29.68, so the headline isn't fully priced in. The deal is cash-funded and the company warns of modest 2026 dilution, limiting near-term earnings shock. Our take: idiosyncratic M&A with clear upside if ALE1 succeeds, but clinical-stage risk is high. We lean bullish on company-specific upside while keeping sizing tight because macro momentum is weak.